Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, reported the exercise of approximately 2.87 million previously issued Series P and Series Q warrants resulting in gross proceeds to the Company of approximately $3.53 million . The warrants
| GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, reported the exercise of approximately 2.87 million previously issued Series P and Series Q warrants resulting in gross proceeds to the Company of approximately $3.53 million. The warrants were issued in the company’s January 2020 warrant inducement transaction. The receipt of the proceeds increases the Company cash on hand as it continues executing on the strategy of acquiring and in-licensing new therapeutic products for development while seeking partners for our existing clinical programs. About Seneca Biopharma, Inc. Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients. Cautionary Statement Regarding Forward Looking Information: This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Seneca’s periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.
SOURCE Seneca Biopharma, Inc. | ||
Company Codes: NASDAQ-NMS:SNCA |
View original content:
